UPS - LEIDER IST IHR BROWSER VERALTET!

Um zukunftsfähig zu sein, wurde unsere aktuelle Webseite für die neuesten Technologien entwickelt.
Daher können bei alten Browsern leider Probleme auftreten.
Damit die neue Börse-Online-Seite richtig funktioniert und Spaß macht, empfehlen wir Ihnen einen dieser aktuellen und kostenlosen Browser herunterzuladen:

Berkeley Lights- Biotech-Wert in ARK ETF enthalten

Seite 1 von 1
neuester Beitrag: 09.06.21 21:19
eröffnet am: 13.04.21 14:31 von: andante Anzahl Beiträge: 7
neuester Beitrag: 09.06.21 21:19 von: andante Leser gesamt: 804
davon Heute: 1
bewertet mit 0 Sternen

957 Postings, 1967 Tage andanteBerkeley Lights- Biotech-Wert in ARK ETF enthalten

 
  
    
13.04.21 14:31
Der Wert hat sich in 2020 nach dem IPO an der Nasdaq auf über 100 Dollar verdoppelt um im ersten Quartal 2021 auf knapp unter 40 Dollar einzubrechen. Aktuell um 40 Dollar notierend wurde womöglich ein charttechnischer Boden gefunden.
Anfang April wurde Berkely nun in die ARK Investment Fonds von Cathy Wood aufgenommen.
Hier könnte ein sehr gutes Chance- Risiko Potenzial vorliegen.  

957 Postings, 1967 Tage andanteARKG ETF

 
  
    
13.04.21 15:02
Hier ist Berkeley inzwischen enthalten:
www.ark-funds.com/arkg

Der Kurs von Berkeley schwankt seit Anfang März 2021 um 50 Dollar/ 40 Euro, nicht um 40 Dollar, wie irrtümlich oben geschrieben. Die niedrigste Notierung lag Ende März bei 42 Dollar/ 36 Euro.

Letzte News:
EMERYVILLE, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- Today, Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, announced the launch of Opto Assure, a series of assays that provides yield and product quality data at an earlier stage in cell line development. The first of the series enables direct detection of product aggregates, ensuring a faster ramp toward volume production by evaluating biotherapeutic protein quality sooner in the antibody therapeutic development process. With Opto Assure, customers can rapidly select clonal cell lines with favorable manufacturability profiles, leading to decreased scale-up costs and better downstream products.

Cell line development has become more challenging with the emergence of complex antibody therapeutic formats. These highly engineered proteins are prone to quality issues including aggregation, by-products, and post-translational modifications, which impact drug manufacturability, shelf life, and safety. Berkeley Lights enhances its technology leadership position in cell line development by going beyond titer assessment in the clone selection process. Opto Assure helps minimize risk of costly late stage failures by identifying clones early on that secrete product with high yield and desired quality.

?We?re excited to empower manufacturers of complex therapeutics, such as bispecifics, to develop better production cell lines faster. As we build out the Opto Assure series, customers can look forward to added capabilities that further reduce resources spent on preventing product failures downstream and ensure a more efficient process,? said John Proctor, Ph.D., SVP of Antibody Therapeutics at Berkeley Lights.

About Berkeley Lights
Berkeley Lights is a leading digital cell biology company focused on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products for our customers. The Berkeley Lights Platform captures deep phenotypic, functional and genotypic information for thousands of single cells in parallel and can also deliver the live biology customers desire in the form of the best cells. Our platform is a fully integrated, end-to-end solution, comprising proprietary consumables, including our OptoSelec chips and reagent kits, advanced automation systems, and application software. We developed the Berkeley Lights Platform to provide the most advanced environment for rapid functional characterization of single cells at scale, the goal of which is to establish an industry standard for our customers throughout their cell-based product value chain.
 

957 Postings, 1967 Tage andanteReport First Quarter 2021

 
  
    
13.04.21 17:08
Berkeley Lights to Report First Quarter 2021 Financial Results on May 11, 2021

EMERYVILLE, Calif., April 12, 2021 (GLOBE NEWSWIRE) -- Berkeley Lights, Inc. (Nasdaq: BLI), a leader in Digital Cell Biology, today announced the company will be reporting financial results for the first quarter 2021 before market open on Tuesday, May 11, 2021. Company management will be webcasting a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time. Live audio of the webcast will be available on the ?Investors? section of the Company?s website at: www.berkeleylights.com. The webcast will be archived and available for replay after the event.  

957 Postings, 1967 Tage andanteaufwärts

 
  
    
14.04.21 17:19
Sie bewegt sich in die richtige Richtung, im Ark ETF wurde Berkeley gestern auch noch mal gekauft
So long  

957 Postings, 1967 Tage andanteDritter Zukauf des ARK G ETF

 
  
    
15.04.21 09:15
Aber sonst haben offenbar viele Berkeley gerade nicht auf dem Schirm. Dann warten wir mal, ob sich das nach den Zahlen am 11.5. ändert.  

957 Postings, 1967 Tage andanteEs geht los

 
  
    
01.06.21 15:33
EMERYVILLE, Calif., June 01, 2021 (GLOBE NEWSWIRE)
Today, Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, announced the release of its TechAccess Subscription model to enable broader customer access to their cutting-edge, single-cell screening technology. The new offering brings requested volume and throughput flexibility to customers who want to access the company?s cell line development and antibody discovery workflows. The all-inclusive subscription provides customers with a comprehensive suite of products, including a Beacon system, software, consumables, service, support, and commercial use rights. Each TechAccess subscription has a renewable 1-year term and provides customers with the turnkey capacity they need and the financial benefits of no up-front capital expense. The all-inclusive offering also provides customers with innovation insurance, providing access to Berkeley Lights? latest technology features and capabilities at no additional cost.

Berkeley Lights has already started signing subscription-based access agreements with customers doing cell line development as well as antibody discovery and expects many more to come. Many customers welcome the capacity-based access model as an alternative to direct purchase of Berkeley Lights technology. Those with lower capacity requirements are particularly eager to take advantage of the significant speed, throughput and quality benefits of the Berkeley Lights platform, under a model that now matches their capacity needs. ?We are thrilled that we can now offer this game-changing technology to our partners and customers as part of our core services,? said Amy He, Senior Director of Bionova Scientific Process Development. "We will be able to deliver high-quality product faster while meeting our need for campaign flexibility with no up-front capital expense.

The release of the TechAccess Subscription model aligns with the upcoming availability of the upgraded Opto Plasma B Discovery 4.0 workflow and Opto Assure for cell line development assays. ?Our customers have been requesting tailored access to our technology and the TechAccess Subscription model fits their specific needs,? said John Proctor, Ph.D., SVP, Antibody Therapeutics Berkeley Lights. ?Since the release, we have seen a positive customer response to this program, which we believe will broaden our served available market and accelerate the adoption of Berkley Lights technology.?

About Berkeley Lights
Berkeley Lights is a leading digital cell biology company focused on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products for our customers. The Berkeley Lights Platform captures deep phenotypic, functional and genotypic information for thousands of single cells in parallel and can also deliver the live biology customers desire in the form of the best cells. Our platform is a fully integrated, end-to-end solution, comprising proprietary consumables, including our OptoSelec chips and reagent kits, advanced automation systems, and application software. We developed the Berkeley Lights Platform to provide the most advanced environment for rapid functional characterization of single cells at scale, the goal of which is to establish an industry standard for our customers throughout their cell-based product value chain.
(...)
Investor Contact: ir@berkeleylights.com  

957 Postings, 1967 Tage andante+ 9 %

 
  
    
09.06.21 21:19
Das wurde aber auch Zeit  

   Antwort einfügen - nach oben